Document is current
Any future updates will be listed below
-
Authors
Hiraoka, Miki
Ariwansa, Dedy
Abiko, Yoshihiro
Paudel, Durga
Yoshida, Shiho
Okamoto, Ken
Sato, Nana
Nagata, Koji
Hirano, Masuharu
-
Funding
Funding for this research was provided by:
the Japan Agency for Medical Research and Development (Seeds A188)
Johnson & Johnson Surgical Vision research grant
Japan Alcon research grant
- License Information
-
More Information
Article History
Received: 8 April 2026
Accepted: 31 July 2026
First Online: 6 August 2026
Declarations
Competing interests: In relation to this manuscript, The University of Tokyo, Health Sciences University of Hokkaido, and Nippon Chemiphar Co., Ltd. have filed a patent application (PCT/JP2021/045045) covering the use of the xanthine oxidoreductase inhibitor NC-2500 for retinal/ocular disease, which is the subject of this study; Miki Hiraoka, Ken Okamoto and Masuharu Hirano are named inventors. Ken Okamoto serves as Chief Scientific Officer (CSO) of PurinoScience Foods. The remaining authors declare no competing interests.
